Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Rigel Pharmaceuticals, Inc. (RIGL)

1.48   0.02 (1.37%) 03-20 09:52
Open: 1.45 Pre. Close: 1.46
High: 1.48 Low: 1.43
Volume: 246,529 Market Cap: 285(M)

Technical analysis

as of: 2023-03-20 9:19:12 AM
Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 1.95     One year: 2.13
Support: Support1: 1.42    Support2: 1.18
Resistance: Resistance1: 1.67    Resistance2: 1.83
Pivot: 1.58
Moving Average: MA(5): 1.59     MA(20): 1.58
MA(100): 1.28     MA(250): 1.5
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 37.9     %D(3): 45.8
RSI: RSI(14): 42.4
52-week: High: 3.28  Low: 0.63
Average Vol(K): 3-Month: 3,314 (K)  10-Days: 6,839 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ RIGL ] has closed above bottom band by 12.7%. Bollinger Bands are 17.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.61 - 1.62 1.62 - 1.63
Low: 1.42 - 1.43 1.43 - 1.44
Close: 1.45 - 1.46 1.46 - 1.47

Company Description

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Headline News

Sat, 18 Mar 2023
Analysts have given Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) a ... - Best Stocks

Thu, 16 Mar 2023
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Consensus ... - MarketBeat

Tue, 14 Mar 2023
Is Rigel Pharmaceuticals Inc (RIGL) Stock at the Top of the Biotechnology Industry? - InvestorsObserver

Mon, 13 Mar 2023
FY2023 Earnings Forecast for Rigel Pharmaceuticals, Inc. (NASDAQ ... - MarketBeat

Thu, 09 Mar 2023
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) institutional owners may be pleased with recent gains after 45% loss over the past year - Simply Wall St

Tue, 07 Mar 2023
Rigel Pharmaceuticals Inc. Q4 Earnings Summary - Nasdaq

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 173 (M)
Shares Float 171 (M)
% Held by Insiders 1.4 (%)
% Held by Institutions 74.9 (%)
Shares Short 5,640 (K)
Shares Short P.Month 6,380 (K)

Stock Financials

EPS -0.18
EPS Est Next Qtl -0.16
EPS Est This Year -0.61
EPS Est Next Year -0.44
Book Value (p.s.) 0.2
Profit Margin (%) -96.3
Operating Margin (%) -92.1
Return on Assets (ttm) -32.8
Return on Equity (ttm) -553.8
Qtrly Rev. Growth -3.1
Gross Profit (p.s.) 0.41
Sales Per Share 0.49
EBITDA (p.s.) -0.46
Qtrly Earnings Growth 0
Operating Cash Flow -71 (M)
Levered Free Cash Flow -42 (M)

Stock Valuations

PE Ratio -8.3
PEG Ratio -0.1
Price to Book value 7.3
Price to Sales 2.93
Price to Cash Flow -3.56

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.